These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33008517)

  • 1. Targeting the 5-HT
    Huang PC; Yang FC; Chang CM; Yang CP
    Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted 5-HT
    Vila-Pueyo M
    Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT
    Edvinsson JCA; Maddahi A; Christiansen IM; Reducha PV; Warfvinge K; Sheykhzade M; Edvinsson L; Haanes KA
    J Headache Pain; 2022 Feb; 23(1):26. PubMed ID: 35177004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
    Raffaelli B; Israel H; Neeb L; Reuter U
    Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM; VanDenBrink AM
    Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
    Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CGRP and 5-HT
    Moreno-Ajona D; Chan C; Villar-Martínez MD; Goadsby PJ
    Headache; 2019 Jul; 59 Suppl 2():3-19. PubMed ID: 31291016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HT1F agonists.
    Steel SJ
    Handb Clin Neurol; 2024; 199():43-50. PubMed ID: 38307661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
    Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
    Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling lasmiditan as a treatment option for migraine.
    Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
    [No Abstract]   [Full Text] [Related]  

  • 14. Lasmiditan for the treatment of migraine.
    Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
    Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Triptans in migraine--here and now (15 years after they were implemented in therapy)].
    Prusiński A; Rozniecki JJ
    Neurol Neurochir Pol; 2005; 39(4 Suppl 1):S68-77. PubMed ID: 16419574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin receptor ligands: treatments of acute migraine and cluster headache.
    Goadsby PJ
    Handb Exp Pharmacol; 2007; (177):129-43. PubMed ID: 17087122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Journey of the Non-Vascular Relief for Migraine: From 'Triptans' To 'Ditans'.
    Xavier AS; Lakshmanan M; Gunaseelan V
    Curr Clin Pharmacol; 2017; 12(1):36-40. PubMed ID: 28425871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of binding, functional activity, and contractile responses of the selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJJC; Zanelli E; Meeus L; Danser AHJ; Gralinski MR; Senese PB; Johnson KW; Kovalchin J; Villalón CM; MaassenVanDenBrink A
    Br J Pharmacol; 2019 Dec; 176(24):4681-4695. PubMed ID: 31418454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lasmiditan for the acute treatment of migraine.
    DeJulio PA; Perese JK; Schuster NM; Oswald JC
    Pain Manag; 2021 Sep; 11(5):437-449. PubMed ID: 33840206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.